Analytical Data
-
Gene name
Ba71V-081
- Application
-
Alternative Names
p72 p73
-
Species
African swine fever virus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22776
-
Expression Region
415-646aa
-
Molecular Weight
33.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Ba71V-081 is a recombinant protein derived from the Ba71V strain of the vesicular stomatitis virus (VSV), a member of the Rhabdoviridae family. Research into Ba71V-081 has garnered attention due to its potential applications in vaccine development and immunotherapy, particularly against viral infections and certain cancers. The recombinant protein serves as a valuable tool for studying viral mechanisms and host interactions, enhancing our understanding of viral pathogenesis. Moreover, because VSV has inherent oncolytic properties, Ba71V-081 is being explored for its ability to selectively target and destroy cancer cells, making it a candidate for novel cancer therapies. Scientists are investigating its immunogenicity and efficacy, as well as the underlying mechanisms by which it may stimulate the immune system to recognize and combat tumors. This research is particularly relevant in the context of developing effective vaccines and therapeutics, as existing treatments often face challenges such as resistance and variable efficacy. Overall, the study of Ba71V-081 represents a promising frontier in virology and cancer treatment, with the potential to yield significant advancements in both viral and oncological therapies.
